Skip to main content
. Author manuscript; available in PMC: 2022 Oct 4.
Published in final edited form as: Phys Biol. 2021 Oct 4;18(6):10.1088/1478-3975/ac267a. doi: 10.1088/1478-3975/ac267a

Figure 5. Arp2/3 activity is required to reduce cytoplasmic pressure and increase epithelial cell migration.

Figure 5.

(A) Representative images of parental MDCK cells co-treated with HGF and the Arp2/3 inhibitors CK666 and CK869, immunostained for cortactin (greyscale). Inhibition of Arp2/3 prevents cortactin-positive lamellipodia from forming (white arrowheads). Bar = 20μm. Quantified in (B) (n ≥ 15, N = 3). *, P < 0.0001 versus control. (C) Inhibiting Arp2/3 activity prevents HGF treatment from reducing the cytoplasmic pressure of parental MDCK cells (n ≥ 30, N = 3). *, P < 0.0001 versus control. (D) Inhibition of Arp2/3 activity prevents HGF treatment from increasing MDCK cell motility (n ≥ 30, N = 3). *, P < 0.0001 versus control. **, P < 0.0001 versus HGF.